On this page:


The DESappear Study: Drug Eluting Scaffold (DESappear)

This study is currently recruiting participants.

Trial website: https://clinicaltrials.gov/ct2/show/NCT02869087 

Trial purpose: The aim of this study is to prospectively collect information to evaluate the safety and performance of the Akesys Prava Sirolimus Eluting Bioresorbable Peripheral scaffold system for the treatment of symptomatic primary atherosclerotic stenoses and occlusions of the superficial femoral artery (SFA). 


Pivotal Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon (ILLUMENATE)

Trial website: https://clinicaltrials.gov/ct2/show/NCT01858428 

Trial purpose: This study is designed to evaluate the safety and efficacy of a Paclitaxel-coated percutaneous transluminal angioplasty (PTA) Catheter in the treatment of patients with peripheral arterial disease.


IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Artery (SFA) and Proximal Popliteal Artery (PPA) (INPACT SFA II)

Trial website: https://clinicaltrials.gov/ct2/show/NCT01566461?term=INPACT+paclitaxel&type=Intr&rank=2 

Trial purpose: The purpose of the study is to demonstrate the safety and efficacy of the IN.PACT Admiral drug-coated balloon (DCB) in comparison to any standard balloon for treatment of peripheral arterial disease (PAD) in the superficial femoral artery and proximal popliteal artery. 

Last updated 17 October 2019.